$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

$bmrn Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000104847724000126 Filed on August 05, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$745.7M	$712.0M
YoY Change	28.28%	19.61%
Cost Of Revenue	$188.5M	$130.5M
YoY Change	51.07%	1.86%
Gross Profit	$557.3M	$581.6M
YoY Change	22.05%	24.48%
Gross Profit Margin	74.73%	81.68%
Selling, General & Admin	$253.5M	$263.0M
YoY Change	13.2%	22.15%
% of Gross Profit	45.48%	45.23%
Research & Development	$184.9M	$183.8M
YoY Change	-3.35%	3.62%
% of Gross Profit	33.18%	31.6%
Depreciation & Amortization	$19.01M	$11.50M
YoY Change	91.98%	-54.76%
% of Gross Profit	3.41%	1.98%
Operating Expenses	$443.4M	$446.8M
YoY Change	6.78%	9.43%
Operating Profit	$113.9M	$120.5M
YoY Change	343.84%	104.61%
Interest Expense	$15.09M	$16.21M
YoY Change	299.18%	83.03%
% of Operating Profit	13.24%	13.46%
Other Income/Expense, Net	$5.463M	-$4.527M
YoY Change	36.58%	-246.84%
Pretax Income	$134.4M	$132.1M
YoY Change	222.64%	86.61%
Income Tax	$28.36M	$24.96M
% Of Pretax Income	21.1%	18.89%
Net Earnings	$106.1M	$107.2M
YoY Change	162.72%	91.25%
Net Earnings / Revenue	14.22%	15.05%
Basic Earnings Per Share	$0.56	$0.56
Diluted Earnings Per Share	$0.54	$0.55
COMMON SHARES
Basic Shares Outstanding	190.4M shares	189.9M shares
Diluted Shares Outstanding	197.1M shares	200.5M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$930.4M	$1.224B
YoY Change	-17.36%	4.56%
Cash & Equivalents	$675.4M	$972.2M
Short-Term Investments	$255.0M	$252.2M
Other Short-Term Assets	$169.3M	$160.4M
YoY Change	-24.71%	-17.05%
Inventory	$1.179B	$1.184B
Prepaid Expenses
Receivables	$777.5M	$691.2M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$3.057B	$3.260B
YoY Change	3.43%	10.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.045B	$1.053B
YoY Change	-2.04%	-1.35%
Goodwill	$196.2M	$196.2M
YoY Change	0.0%	0.0%
Intangibles	$260.9M	$265.5M
YoY Change	-13.74%	-14.44%
Long-Term Investments	$568.8M	$563.8M
YoY Change	3.79%	46.14%
Other Assets	$199.3M	$190.8M
YoY Change	20.75%	-88.46%
Total Long-Term Assets	$3.795B	$3.807B
YoY Change	-0.22%	5.38%
TOTAL ASSETS
Total Short-Term Assets	$3.057B	$3.260B
Total Long-Term Assets	$3.795B	$3.807B
Total Assets	$6.851B	$7.067B
YoY Change	1.38%	7.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$312.3M	$257.4M
YoY Change	3.62%	-7.39%
Accrued Expenses	$378.6M	$298.4M
YoY Change	8.02%	2.53%
Deferred Revenue	$2.346M	$1.912M
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$494.8M
YoY Change	-100.0%
Total Short-Term Liabilities	$715.7M	$1.067B
YoY Change	-38.48%	78.71%
LONG-TERM LIABILITIES
Long-Term Debt	$594.6M	$594.1M
YoY Change	0.34%	-45.24%
Other Long-Term Liabilities	$127.5M	$119.4M
YoY Change	20.92%	21.66%
Total Long-Term Liabilities	$127.5M	$119.4M
YoY Change	20.92%	-89.91%
TOTAL LIABILITIES
Total Short-Term Liabilities	$715.7M	$1.067B
Total Long-Term Liabilities	$127.5M	$119.4M
Total Liabilities	$1.438B	$1.781B
YoY Change	-22.75%	0.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$319.6M	-$425.7M
YoY Change	-50.21%	-37.61%
Common Stock	$5.740B	$5.697B
YoY Change	3.56%	3.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.413B	$5.286B
YoY Change
Total Liabilities & Shareholders Equity	$6.851B	$7.067B
YoY Change	1.38%	7.68%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$106.1M	$107.2M
YoY Change	162.72%	91.25%
Depreciation, Depletion And Amortization	$19.01M	$11.50M
YoY Change	91.98%	-54.76%
Cash From Operating Activities	$221.5M	$118.8M
YoY Change	63.21%	69.51%
INVESTING ACTIVITIES
Capital Expenditures	$21.18M	$21.84M
YoY Change	-9.5%	-3.92%
Acquisitions
YoY Change
Other Investing Activities	$5.019M	$112.3M
YoY Change	-122.41%	114.92%
Cash From Investing Activities	-$16.16M	$90.48M
YoY Change	-64.72%	206.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-499.1M	12.61M
YoY Change	62290.62%	5.43%
NET CHANGE
Cash From Operating Activities	221.5M	118.8M
Cash From Investing Activities	-16.16M	90.48M
Cash From Financing Activities	-499.1M	12.61M
Net Change In Cash	-293.8M	221.9M
YoY Change	-429.74%	98.87%
FREE CASH FLOW
Cash From Operating Activities	$221.5M	$118.8M
Capital Expenditures	$21.18M	$21.84M
Free Cash Flow	$200.3M	$96.92M
YoY Change	78.37%	104.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2058000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	4533000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	103857000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5108000	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-7455000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	4782827000	usd
	us-gaap	Net Income Loss NetIncomeLoss	106892000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51840000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	972150000	usd
	us-gaap	Depreciation Depreciation	24100000	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	7684000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	usd
	bmrn	Asset Impairment Charges And Other Non Cash Adjustments AssetImpairmentChargesAndOtherNonCashAdjustments	12650000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-361000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	145831000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	56476000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	53430000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5616000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-25093000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	7104000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3870000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	46039000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	491063000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	444049000	usd
	bmrn	Proceeds From Sale Of Nonfinancial Assets ProceedsFromSaleOfNonfinancialAssets	0	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1457000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	76244000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	36618000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	66739000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	60000	usd
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1635000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-30181000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-28779000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5227000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2981000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	217023000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-30150000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	755127000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	724531000	usd
	us-gaap	Interest Paid Net InterestPaidNet	5126000	usd
	us-gaap	Interest Paid Net InterestPaidNet	5175000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	22884000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	28183000	usd
	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	11941000	usd
	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Fixed Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseFixedAssets	8669000	usd
	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	8290000	usd
	bmrn	Supplemental Accounts Payable And Accrued Liabilities Increase Decrease Intangible Assets SupplementalAccountsPayableAndAccruedLiabilitiesIncreaseDecreaseIntangibleAssets	2344000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management’s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management performed an evaluation of the Company’s activities through the date of filing of this Quarterly Report on Form 10-Q to determine if there were any subsequent events that occurred subsequent to the balance sheet date and prior to filing this Quarterly Report on Form 10-Q, that would require recognition or disclosure in the Condensed Consolidated Financial Statements. Further to this evaluation, the Company has included a subsequent event noted relating to the maturity and settlement of the Company’s convertible notes due in August 2024 that is discussed in </span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i3d2a3ac006bb417580d8603bb5789356_49" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Note </a><a href="#i3d2a3ac006bb417580d8603bb5789356_49" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6 </a><a href="#i3d2a3ac006bb417580d8603bb5789356_49" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">- </a><a href="#i3d2a3ac006bb417580d8603bb5789356_49" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Deb</a><a href="#i3d2a3ac006bb417580d8603bb5789356_49" style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">t</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">.</span></div>
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1783242000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	814000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2622000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1781434000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	972150000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	252201000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	557083000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1683827000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4388000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3270000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1684945000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	755127000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	318683000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	611135000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Impairment Loss Annual Amount EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount	12600000	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	154153000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	155704000	usd
CY2024Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	605770000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	571107000	usd
CY2024Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	423698000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	380372000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1183621000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1107183000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1962948000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1933222000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	910050000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	867089000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1052898000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1066133000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	11500000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	9400000	usd
	us-gaap	Depreciation Depreciation	19700000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	710533000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	710011000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	445000000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	415310000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	265533000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	294701000	usd
CY2024Q1	bmrn	Milestone Payments Received MilestonePaymentsReceived	10000000	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	257412000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	315509000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	147737000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	201067000	usd
CY2024Q2	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	113432000	usd
CY2023Q4	bmrn	Accrued Government And Other Rebates AccruedGovernmentAndOtherRebates	96179000	usd
CY2024Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	18864000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2651000	usd
CY2024Q2	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	10689000	usd
CY2023Q4	bmrn	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	8779000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	33853000	usd
CY2024Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	7667000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	14299000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1912000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4620000	usd
CY2024Q2	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	7103000	usd
CY2023Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	6190000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	572500000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	683147000	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	38187000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	9065000	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	8941000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	42024000	usd
	us-gaap	Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths	21200000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1100000000	usd
CY2024Q2	us-gaap	Convertible Debt ConvertibleDebt	1088953000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	1086972000	usd
CY2024Q2	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1068549000	usd
CY2023Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	1107548000	usd
CY2024Q2	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	30867000	usd
CY2024Q2	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	3181000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-159000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	27845000	usd
CY2023Q2	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	-7398000	usd
CY2023Q2	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	651000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-154000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7895000	usd
	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	57485000	usd
	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	2566000	usd
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	-668000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	55587000	usd
	us-gaap	Oci Before Reclassifications Before Tax Attributable To Parent OciBeforeReclassificationsBeforeTaxAttributableToParent	-10010000	usd
	us-gaap	Reclassification From Aoci Current Period Before Tax Attributable To Parent ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent	3665000	usd
	us-gaap	Other Comprehensive Income Loss Tax Portion Attributable To Parent1 OtherComprehensiveIncomeLossTaxPortionAttributableToParent1	1075000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-14750000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	712029000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	595275000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1360862000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1191690000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47914000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50162000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	106163000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	103857000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	107174000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	56040000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	195836000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	106892000	usd
CY2024Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2769000	usd
CY2023Q2	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	937000	usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	5538000	usd
	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	1873000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	109943000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	56977000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	201374000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	108765000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	190114000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	187948000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	189490000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	187311000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	200505000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194998000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	200137000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	194756000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.56
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.03
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.57
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.55
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.56
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10362000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13081000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10106000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12686000	shares
	bmrn	Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestones	495600000	usd
CY2024Q2	bmrn	Contingent Payments Reasonably Possible Upon Achievement Of Certain Development And Regulatory Activities Commercial Sales And Licensing Milestones To Be Paid Due In Rolling Next12 Months ContingentPaymentsReasonablyPossibleUponAchievementOfCertainDevelopmentAndRegulatoryActivitiesCommercialSalesAndLicensingMilestonesToBePaidDueInRollingNext12Months	10900000	usd
CY2024Q2	us-gaap	Purchase Obligation PurchaseObligation	473000000.0	usd
CY2024Q2	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	291100000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001048477-24-000126-index-headers.html	Edgar Link	pending
0001048477-24-000126-index.html	Edgar Link	pending
0001048477-24-000126.txt	Edgar Link	pending
0001048477-24-000126-xbrl.zip	Edgar Link	pending
bmrn-20240630.htm	Edgar Link	pending
bmrn-20240630.xsd	Edgar Link	pending
bmrn-exx101xq22024.htm	Edgar Link	pending
bmrn-exx102xq2x2024.htm	Edgar Link	pending
bmrn-exx311xq22024.htm	Edgar Link	pending
bmrn-exx312xq22024.htm	Edgar Link	pending
bmrn-exx321xq22024.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
bmrn-20240630_def.xml	Edgar Link	unprocessable
bmrn-20240630_lab.xml	Edgar Link	unprocessable
bmrn-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bmrn-20240630_htm.xml	Edgar Link	completed
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bmrn-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2024 Q3 Form 10-Q Financial Statement

#000104847724000126 Filed on August 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2024 Q3 Form 10-Q Financial Statement

#000104847724000126 Filed on August 05, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn